Literature DB >> 8433709

High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component.

R J Boackle1, M H Connor, J Vesely.   

Abstract

Non-Immunoglobulin Salivary Agglutinins (NIA) which directly bind to microbes [including HIV] were studied for their potential to activate the first complement component (C1). It was determined that NIA had the same specific activity as heat aggregated IgG in binding to C1q and in activating C1. In order to determine the region of C1q which bound to NIA, C1q globular heads and C1q stems (collagen-like regions) were prepared and separated via a Western blot procedure. NIA bound principally to the globular heads of C1q and weakly to the collagen-like stem region. NIA were also studied for their potential to activate native C1 in normal human serum. Heat-aggregated IgG and cardiolipin served as positive controls. It was observed that incubation of isolated NIA with fresh normal human serum resulted in the formation of sodium dodecyl sulfate (SDS)-irreversible complexes of activated C1r-C1 inhibitor and activated C1s-C1 inhibitor and in activated C1s mediated C4 conversion. This indicated that isolated NIA had the potential to directly and effectively mediate classical complement pathway activation. Preincubation of NIA with C1q, blocked NIA mediated C1r and C1s activation and C4 conversion. The concn of NIA required to activate C1r and C1s was similar to that of heat-aggregated human IgG. In kinetic ELISA, NIA or aggregated IgG (positive controls) were first immobilized on microtiter plates, blocked with gelatin then incubated with fresh human serum as a source of complement. Depositions of C4b, C3b and iC3b substantiated that the complement system was effectively activated by immobilized NIA. The optimal relative NaCl concn for C4b deposition was 0.11 M. While pre-incubation of NIA with C1q blocked the subsequent C1 fixing potential of NIA, pre-incubation of NIA with rgp160 [HIV-1] or fibronectin did not interfere with the potential of NIA to fix C1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8433709     DOI: 10.1016/0161-5890(93)90059-k

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  22 in total

1.  Binding of salivary agglutinin to IgA.

Authors:  Antoon J M Ligtenberg; Floris J Bikker; Jolanda M A De Blieck-Hogervorst; Enno C I Veerman; Arie V Nieuw Amerongen
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

Review 2.  Structural and functional anatomy of the globular domain of complement protein C1q.

Authors:  Uday Kishore; Rohit Ghai; Trevor J Greenhough; Annette K Shrive; Domenico M Bonifati; Mihaela G Gadjeva; Patrick Waters; Mihaela S Kojouharova; Trinad Chakraborty; Alok Agrawal
Journal:  Immunol Lett       Date:  2004-09       Impact factor: 3.685

3.  Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).

Authors:  Robert J Boackle; Quang L Nguyen; Renata S Leite; Xiaofeng Yang; Jana Vesely
Journal:  Mol Immunol       Date:  2005-03-05       Impact factor: 4.407

4.  Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.

Authors:  Hee Young Hwang; Marcus R Duvall; Stephen Tomlinson; Robert J Boackle
Journal:  Mol Immunol       Date:  2008-03-03       Impact factor: 4.407

Review 5.  Streptococcus adherence and colonization.

Authors:  Angela H Nobbs; Richard J Lamont; Howard F Jenkinson
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

6.  C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.

Authors:  C H Chen; C F Lam; R J Boackle
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

7.  Variant size- and glycoforms of the scavenger receptor cysteine-rich protein gp-340 with differential bacterial aggregation.

Authors:  Christer Eriksson; Lars Frängsmyr; Liza Danielsson Niemi; Vuokko Loimaranta; Ulf Holmskov; Tomas Bergman; Hakon Leffler; Howard F Jenkinson; Nicklas Strömberg
Journal:  Glycoconj J       Date:  2007-01-23       Impact factor: 2.916

8.  The Human Glycoprotein Salivary Agglutinin Inhibits the Interaction of DC-SIGN and Langerin with Oral Micro-Organisms.

Authors:  Martine A Boks; Sabrina T G Gunput; Ilona Kosten; Susan Gibbs; Sandra J van Vliet; Antoon J M Ligtenberg; Yvette van Kooyk
Journal:  J Innate Immun       Date:  2016-04-16       Impact factor: 7.349

9.  Respiratory Deleted in Malignant Brain Tumours 1 (DMBT1) levels increase during lung maturation and infection.

Authors:  H Müller; C End; C Weiss; M Renner; A Bhandiwad; B M Helmke; N Gassler; M Hafner; A Poustka; J Mollenhauer; J Poeschl
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

10.  Effect of salivary agglutination on oral streptococcal clearance by human polymorphonuclear neutrophil granulocytes.

Authors:  A Itzek; Z Chen; J Merritt; J Kreth
Journal:  Mol Oral Microbiol       Date:  2016-07-10       Impact factor: 3.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.